ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,460.48
      -0.41%
      US Tech 100
      19,181.60
      -0.43%
      Dow Jones
      39,118.86
      -0.12%
      Brent Oil
      85.235
      0.15%
      Bitcoin
      63,424.90
      1.21%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Incyte Corporation (INCY)

      7. Incyte Corporation (INCY) News

      INCY

      Incyte (INCY)

      Incyte Corporation
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:INCY
      DateTimeSourceHeadlineSymbolCompany
      12/05/20227:00AMPR Newswire (US)Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical OncologyNASDAQ:INCYIncyte Corporation
      12/02/20228:30AMBusiness WireIncyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast AsiaNASDAQ:INCYIncyte Corporation
      11/17/20228:00AMBusiness WireIncyte to Present at Upcoming Investor ConferencesNASDAQ:INCYIncyte Corporation
      11/16/20228:45PMTipRanksRBC Capital Reaffirms Their Buy Rating on Incyte (INCY)NASDAQ:INCYIncyte Corporation
      11/07/20228:15AMBusiness WireIncyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid TumorsNASDAQ:INCYIncyte Corporation
      11/07/20228:00AMBusiness WireData From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingNASDAQ:INCYIncyte Corporation
      11/04/20223:30PMBusiness WirePlus de 50 abstracts du solide portefeuille d'oncologie d'Incyte seront présentés lors du 64e congrès annuel de l'ASHNASDAQ:INCYIncyte Corporation
      11/04/20225:32AMBusiness Wire64. ASH-Jahrestagung: Incyte präsentiert mehr als 50 Abstracts zu seinem robusten Onkologie-PortfolioNASDAQ:INCYIncyte Corporation
      11/04/20221:05AMTipRanksSVB Securities Remains a Sell on Incyte (INCY)NASDAQ:INCYIncyte Corporation
      11/03/202210:24AMBusiness WireMore than 50 Abstracts from Incyte’s Robust Oncology Portfolio to be Featured at the 64th ASH Annual MeetingNASDAQ:INCYIncyte Corporation
      11/03/20221:40AMTipRanksAnalysts Offer Insights on Healthcare Companies: Incyte (INCY) and Avanos Medical (AVNS)NASDAQ:INCYIncyte Corporation
      11/02/20228:37AMTipRanksIncyte (INCY) Receives a Hold from Morgan StanleyNASDAQ:INCYIncyte Corporation
      11/01/20224:08PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:INCYIncyte Corporation
      11/01/20228:05AMTipRanksMizuho Securities Sticks to Their Hold Rating for Incyte (INCY)NASDAQ:INCYIncyte Corporation
      11/01/20227:00AMBusiness WireIncyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical ProgramsNASDAQ:INCYIncyte Corporation
      10/28/20224:15AMTipRanksIncyte (INCY) Receives a Hold from Mizuho SecuritiesNASDAQ:INCYIncyte Corporation
      10/20/20229:30AMBusiness WireDonnées de phase 3 décisives montrant des améliorations significatives de la repigmentation faciale et corporelle totale avec la crème de ruxolitinib (Opzelura™) chez les personnes souffrant de vitiligo publiées...NASDAQ:INCYIncyte Corporation
      10/20/20229:21AMBusiness WireDaten aus zulassungsrelevantem Phase-3-Programm, die signifikant verbesserte Repigmentierung im Gesichtsbereich und am gesamten Körper mit Ruxolitinib-Creme (Opzelura™) bei Vitiligo zeigen, im New England Journal of Medicine veröffentlichtNASDAQ:INCYIncyte Corporation
      10/19/20226:17PMBusiness WirePivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of MedicineNASDAQ:INCYIncyte Corporation
      10/18/20228:43AMTipRanksAnalysts Offer Insights on Healthcare Companies: Incyte (INCY), Apellis Pharmaceuticals (APLS) and NGM Biopharmaceuticals (NGM)NASDAQ:INCYIncyte Corporation
      10/11/20228:00AMBusiness WireIncyte to Report Third Quarter Financial ResultsNASDAQ:INCYIncyte Corporation
      10/06/20226:12PMGlobeNewswire Inc.Knight Therapeutics Announces Regulatory Submission for Tafasitamab in BrazilNASDAQ:INCYIncyte Corporation
      10/05/20225:02PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      10/04/20224:19PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      10/04/20224:05PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      10/04/20224:02PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      10/04/20228:00AMBusiness WireIncyte Names New Member to Its Board of DirectorsNASDAQ:INCYIncyte Corporation
      10/04/20227:31AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INCYIncyte Corporation
      10/03/20224:34PMBusiness WireIncyte sur le point d'acquérir Villaris Therapeutics, soutenu par Medicxi, et Auremolimab (VM6), un anticorps monoclonal anti-IL-15RβNASDAQ:INCYIncyte Corporation
      10/03/20222:22PMBusiness WireIncyte gibt Vereinbarung zur Übernahme des von Medicxi unterstützten Unternehmens Villaris Therapeutics sowie von Auremolimab (VM6), einem monoklonalen Anti-IL-15Rβ-Antikörper, bekanntNASDAQ:INCYIncyte Corporation
       Showing the most relevant articles for your search:NASDAQ:INCY